AI Article Synopsis
- Antibody-drug conjugates (ADCs) are an innovative cancer treatment strategy that targets specific receptors on tumor cells, delivering cytotoxic drugs directly into those cells.
- ADCs have shown significant success in improving treatment and survival rates for breast cancer patients, especially those with HER-2-positive tumors.
- Despite their benefits, challenges like drug toxicity and resistance must be addressed, and further research is necessary to enhance the effectiveness of ADCs in personalized breast cancer treatments.
Article Abstract
Antibody-drug conjugates (ADCs) have garnered significant attention as an innovative therapeutic strategy in cancer treatment. The mechanism of action for ADCs involves the targeted delivery of antibodies to specific receptors, followed by the release of cytotoxic payloads directly into tumor cells. In recent years, ADCs have made substantial progress in the treatment of breast cancer (BC), particularly demonstrating significant efficacy in the human epidermal growth factor receptor-2 (HER-2)-positive subgroup. Clinical evidence indicates that ADCs have notably improved treatment efficacy and survival outcomes for BC patients. However, challenges such as drug toxicities and the emergence of drug resistance necessitate further research and discussion. In this paper, we will summarize the advances in ADCs targeting various receptors in BC patients and explore the challenges and future directions in this field. We anticipate that the increasing availability of ADCs will lead to more effective and personalized treatment options for BC patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/carcin/bgae082 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!